DHA may only be useful in pre-emptive strikes against Alzheimer's
This article was originally published in Scrip
Alzheimer's patients with mild to moderate symptoms are probably wasting their time taking supplements containing docosahexaenoic acid (DHA), the most abundant long-chain polyunsaturated fatty acid in the brain, according to a study published in this week's Journal of the American Medical Association (JAMA). However, the authors do suggest that there may still be some value giving DHA earlier in the course of the disease and before patients display overt dementia.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.